Literature DB >> 16210377

Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors.

Rajan Singh1, Jorge N Artaza, Wayne E Taylor, Melissa Braga, Xin Yuan, Nestor F Gonzalez-Cadavid, Shalender Bhasin.   

Abstract

Testosterone supplementation in men decreases fat mass; however, the mechanisms by which it inhibits fat mass are unknown. We hypothesized that testosterone inhibits adipogenic differentiation of preadipocytes by activation of androgen receptor (AR)/beta-catenin interaction and subsequent translocation of this complex to the nucleus thereby bypassing canonical Wnt signaling. We tested this hypothesis in 3T3-L1 cells that differentiate to form fat cells in adipogenic medium. We found that these cells express AR and that testosterone and dihydrotestosterone dose-dependently inhibited adipogenic differentiation as analyzed by Oil Red O staining and down-regulation of CCAAT/enhancer binding protein-alpha and -delta and peroxisome proliferator-activated receptor-gamma2 protein and mRNA. These inhibitory effects of androgens were partially blocked by flutamide or bicalutamide. Androgen treatment was associated with nuclear translocation of beta-catenin and AR. Immunoprecipitation studies demonstrated association of beta-catenin with AR and T-cell factor 4 (TCF4) in the presence of androgens. Transfection of TCF4 cDNA inhibited adipogenic differentiation, whereas a dominant negative TCF4 cDNA construct induced adipogenesis and blocked testosterone's inhibitory effects. Our gene array analysis indicates that testosterone treatment led to activation of some Wnt target genes. Expression of constitutively activated AR fused with VP-16 did not inhibit the expression of CCAAT/enhancer binding protein-alpha in the absence of androgens. Testosterone and dihydrotestosterone inhibit adipocyte differentiation in vitro through an AR-mediated nuclear translocation of beta-catenin and activation of downstream Wnt signaling. These data provide evidence for a regulatory role for androgens in inhibiting adipogenic differentiation and a mechanistic explanation consistent with the observed reduction in fat mass in men treated with androgens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210377      PMCID: PMC4417624          DOI: 10.1210/en.2004-1649

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  51 in total

Review 1.  Wnt signaling and cancer.

Authors:  P Polakis
Journal:  Genes Dev       Date:  2000-08-01       Impact factor: 11.361

2.  C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway.

Authors:  Evan D Rosen; Chung-Hsin Hsu; Xinzhong Wang; Shuichi Sakai; Mason W Freeman; Frank J Gonzalez; Bruce M Spiegelman
Journal:  Genes Dev       Date:  2002-01-01       Impact factor: 11.361

3.  Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2.

Authors:  M N Dieudonne; R Pecquery; M C Leneveu; Y Giudicelli
Journal:  Endocrinology       Date:  2000-02       Impact factor: 4.736

4.  Signaling pathways through which insulin regulates CCAAT/enhancer binding protein alpha (C/EBPalpha) phosphorylation and gene expression in 3T3-L1 adipocytes. Correlation with GLUT4 gene expression.

Authors:  N Hemati; S E Ross; R L Erickson; G E Groblewski; O A MacDougald
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

5.  Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells.

Authors:  John E Pawlowski; Jessica R Ertel; Melissa P Allen; Mei Xu; Cheryl Butler; Elizabeth M Wilson; Margaret E Wierman
Journal:  J Biol Chem       Date:  2002-03-26       Impact factor: 5.157

Review 6.  The subcellular destinations of APC proteins.

Authors:  Mariann Bienz
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

7.  SRY interacts with and negatively regulates androgen receptor transcriptional activity.

Authors:  X Yuan; M L Lu; T Li; S P Balk
Journal:  J Biol Chem       Date:  2001-10-03       Impact factor: 5.157

8.  Testosterone dose-response relationships in healthy young men.

Authors:  S Bhasin; L Woodhouse; R Casaburi; A B Singh; D Bhasin; N Berman; X Chen; K E Yarasheski; L Magliano; C Dzekov; J Dzekov; R Bross; J Phillips; I Sinha-Hikim; R Shen; T W Storer
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

9.  Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway.

Authors:  V J Wielenga; R Smits; V Korinek; L Smit; M Kielman; R Fodde; H Clevers; S T Pals
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

10.  Wnt10b inhibits development of white and brown adipose tissues.

Authors:  Kenneth A Longo; Wendy S Wright; Sona Kang; Isabelle Gerin; Shian-Huey Chiang; Peter C Lucas; Mark R Opp; Ormond A MacDougald
Journal:  J Biol Chem       Date:  2004-06-09       Impact factor: 5.157

View more
  122 in total

1.  Testosterone inhibits transforming growth factor-β signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action.

Authors:  Melissa Braga; Shalender Bhasin; Ravi Jasuja; Shehla Pervin; Rajan Singh
Journal:  Mol Cell Endocrinol       Date:  2011-11-25       Impact factor: 4.102

2.  Topical androgen antagonism promotes cutaneous wound healing without systemic androgen deprivation by blocking β-catenin nuclear translocation and cross-talk with TGF-β signaling in keratinocytes.

Authors:  Gianluca Toraldo; Shalender Bhasin; Mena Bakhit; Wen Guo; Carlo Serra; Joshua D Safer; Jag Bhawan; Ravi Jasuja
Journal:  Wound Repair Regen       Date:  2012 Jan-Feb       Impact factor: 3.617

3.  Tissue-selective regulation of androgen-responsive genes.

Authors:  Maya Otto-Duessel; Miaoling He; Jeremy O Jones
Journal:  Endocr Res       Date:  2012-05-16       Impact factor: 1.720

4.  Dehydroepiandrosterone administration or G{alpha}q overexpression induces {beta}-catenin/T-Cell factor signaling and growth via increasing association of estrogen receptor-{beta}/Dishevelled2 in androgen-independent prostate cancer cells.

Authors:  Xunxian Liu; Julia T Arnold; Marc R Blackman
Journal:  Endocrinology       Date:  2010-02-22       Impact factor: 4.736

5.  Androgen-induced PSA expression requires not only activation of AR but also endogenous IGF-I or IGF-I/PI3K/Akt signaling in human prostate cancer epithelial cells.

Authors:  Xunxian Liu; Renee Y Choi; Shayma M Jawad; Julia T Arnold
Journal:  Prostate       Date:  2010-10-28       Impact factor: 4.104

Review 6.  Pathophysiology of Aortic Valve Stenosis: Is It Both Fibrocalcific and Sex Specific?

Authors:  Yoginee Sritharen; Maurice Enriquez-Sarano; Hartzell V Schaff; Grace Casaclang-Verzosa; Jordan D Miller
Journal:  Physiology (Bethesda)       Date:  2017-05

Review 7.  Wnt/beta-catenin signaling in adipogenesis and metabolism.

Authors:  Tyler C Prestwich; Ormond A Macdougald
Journal:  Curr Opin Cell Biol       Date:  2007-11-09       Impact factor: 8.382

8.  Estrogen sulfotransferase inhibits adipocyte differentiation.

Authors:  Taira Wada; Chibueze A Ihunnah; Jie Gao; Xiaojuan Chai; Su Zeng; Brian J Philips; J Peter Rubin; Kacey G Marra; Wen Xie
Journal:  Mol Endocrinol       Date:  2011-08-04

9.  Keratinocyte growth inhibition through the modification of Wnt signaling by androgen in balding dermal papilla cells.

Authors:  Tomoko Kitagawa; Ken-Ichi Matsuda; Shigeki Inui; Hideya Takenaka; Norito Katoh; Satoshi Itami; Saburo Kishimoto; Mitsuhiro Kawata
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

Review 10.  The use of phosphodiesterase 5 inhibitors with concomitant medications.

Authors:  G Corona; E Razzoli; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2008-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.